Introduction
Although surgery, radiation and chemotherapy all result in reducing the bulk of the tumor mass, tumor recurrence and metastases are still universal (1) .
Recently, cancer progression has been thought to be driven by cancer stem cells (CSCs), which have the ability to self-renew, show therapeutic resistance and give rise to relatively differentiated cells (2) . In hepatocellular carcinoma (HCC), several markers, such as EpCAM, OV6, CD90, CD24 and a side population fraction, have been identified for the enrichment of hepatic CSCs (3) (4) (5) (6) (7) (8) . In our previous studies, we have demonstrated that CD133 + CSCs in HCC cell lines were distinctive for their high clonogenicity in vitro and high tumorigenicity in an immunodeficient mouse xenograft model. In addition, this cell population could be further characterized by the co-expression of CD133
and CD44 (9, 10) . The CD133 + CSCs in HCC exhibited a preferential expression of stem-cell-related genes and were more resistant to chemotherapeutic agents as a result of the upregulation of ATP-binding cassette (ABC) superfamily transporters.
Bone morphogenetic proteins (BMPs) have been linked to several aspects of embryonic liver development (11) . BMPs are a subgroup of the TGF-ȕ superfamily members, which elicit their cellular effects via specific membrane receptors. Different combinations of type II receptors (BMPRII) with type I receptors (BMPR1A or BMPR1B) determine the specificity for the ligands eliciting different biological processes (12) . The activated BMPRI phosphorylates receptor-regulated SMAD1/5/8 proteins, which can assemble into heteromeric complexes with SMAD4 and subsequently translocate into the nucleus to regulate the transcription of target genes (13) . SMAD6 is one of the inhibitory SMADs, and its expression is induced by BMP-activated SMAD1/5/8, creating a negative feedback loop that interferes with BMP signaling (14) .
BMP signaling has been shown to promote CSCs differentiation in the brain and colon and to facilitate brain or colon xenograft tumor eradication (15, 16) . Therefore, BMPs have been proposed as a treatment option for glioblastoma and colorectal tumors. Here, we demonstrated that high-dose exogenous BMP4 exhibited potent differentiation therapy activity against CSCs in HCC; however, low-dose or endogenous BMP4 contributed to promote CD133 protein expression. Endogenous BMP signaling target gene, SMAD6 protein expression is positively correlated to CD133 protein expression in HCC. We also found that BMP4 could induce Erk1/2 activation in a time-and dose-dependent manner, and short-term exposure to high-level Erk1/2 phosphorylation is sufficient for BMP4-dependent CD133 expression reduction. The CDM consisted of a 1:1 mixture of neurobasal medium and DMEM/F12 medium supplemented with 0.5× N2, 0.5× B27 supplements, 0.1% BSA, 2 mM glutamine and 0.1 mM 2-mercaptoethanol, growth factors including 10 ng/ml BMP4 (Sigma-Aldrich), 10 ng/ml basic fibroblast growth factor (bFGF) (Millipore), 10 ng/ml epithelial growth factor (EGF) (Millipore), 20 ng/ml 
Statistical analysis
The experimental data were presented as the mean ± SD and analyzed using the Student's t-test. p < 0.05 was considered statistically significant. Fig. 2A ).
We then explored the effects of different doses of BMP4 on the differentiation of CSCs. CD133 + and CD133 -PLC/PRF/5 cells were cultured in a monolayer with serum-free CDM added with different doses of BMP4 ranging from 0 ng/ml to 100 ng/ml for 6 days. We found that in CD133 + cells, 30 ng/ml of BMP4 could induce the downregulation of CD133 expression, and the downregulation was most obvious after stimulation with 100 ng/ml BMP4 (Fig.   1A ). Subsequently, we found that a 50 ng/ml dose showed a sufficient 1D ).
To determine the effect of exogenous BMP4 on the cell proliferation and apoptosis in HCC, we incubated the cells with different doses of BMP4 in the media and found that although lose-dose BMP4 (10 ng/ml) increased the cell proliferation in PLC/PRF/5, high-dose BMP4 (50~100 ng/ml) inhibited cell growth (Fig. 1C ). The cell apoptosis was not significantly influenced after high-dose BMP4 treatment ( Supplementary Fig. 2B ).
BMP4 could induce the differentiation of HCC CSCs
Cancer cells cultured in suspension may form spheroids that have been shown to be an efficient way to enrich CSCs. The number and size of the spheres may reflect the self-renewal capability of these cell populations (19) . Here, 
BMP4 inhibits the self-renewal and tumorigenic capacity of HCC CSCs
Sorted CD133 +/-PLC/PRF/5 cells were cultured in suspension in CDM or in monolayers, and BMP4 was added to observe their differentiation for 6 days.
To evaluate the alteration of the self-renewal capability of these cells, we first compared their clonogenicity by anchorage-independent growth assays in soft agar. The results showed that the CD133 + HCC cells first cultured with BMP4 possessed lower colony formation efficiency (CFE) than that of CD133 + cells continually cultured in CDM (Fig. 3A) . However, the CFE of CD133 -HCC cells 
consistently increased their sensitivity to these two agents.
Based on our previous findings that HCC CSCs were more resistant to chemotherapeutic agents as a result of the upregulation of the superfamily of ABC transporters, we analyzed ABCG2 expression in PLC/PRF/5. We found clear reductions in ABCG2 expression after BMP4 treatment (Fig. 4B) . In HCC, the expression and functional status of ABCG2 is reported to be closely associated with the side population (SP), a minor subset of cells with the unique capacity to extrude Hoechst 33342 (22) . However, few SP cells could be detected in PLC/PRF/5 (unpublished data), we detected the alteration of the SP proportion in MHCC-97L cells. We found that ABCG2 expression was depressed in sorted or unsorted MHCC-97L cells after BMP4 treatment (Fig.   4C ). As shown in Figure 4D , the SP proportion was decreased from 5.1% to 2.3% after BMP4 induction, suggesting that BMP4 may also possess a pro-differentiation effect on the SP population in HCC.
Exogenous BMP4 induces the activation of the canonical BMP/SMAD signaling pathway in HCC
To investigate the effect of canonical BMP signaling in BMP4-induced differentiation, we first examined the activation of the BMP4 signaling pathway.
Nearly all of the HCC cell lines analyzed were found to express BMPRIa and BMPRIb proteins (Fig. 5A, Supplementary Fig. 4A ) by Western blot, and in human primary HCC tissues, the positive staining of BMPRIa and BMPRIb Supplementary   Fig. 4B ). We also observed that SMAD6 overexpression was induced by BMP4 treatment in SMMC-7721 cells ( Supplementary Fig. 4A ).
In many cases, the heterotetramer SMAD1/5/8-SMAD4 complex is required for BMPs signaling. siRNA oligonucleotides specifically targeting SMAD4 were synthesized, and the knockdown efficiency was confirmed ( Supplementary Fig.   4C ). As shown in Figure 5D , the downregulation of CD133 protein expression induced by BMP4 treatment was attenuated after SMAD4 knockdown, demonstrated that the BMP4 pro-differentiation effect was a consequence of its canonical signaling activation.
Endogenous BMP4 inversely contributes to CD133 expression in HCC
For the hepatic progenitor expansion medium (CDM) also contains a low concentration of BMP4, we then explored the effects of different doses, especially low-dose BMP4 on CSC differentiation. As shown in Figure 1A , compared to low-dose BMP4 groups (2.5-10 ng/ml), CD133 expression was also downregulated with no exogenous BMP4 present in vitro.
Endogenous BMP4 mRNA and protein were preferentially expressed in
CD133
+ CSCs in HCC cell lines (Fig. 6A ) and in two primary cell lines (Supplementary Figure 5A) . As BMP4 is a secretary growth factor (24), secretary BMP4 in the culture supernatant was also analyzed, the results
showed that the quantification of BMP4 was at a higher lever in the CD133 (Fig. 6D) . We also found that SMAD6 was differentially expressed in HCC cell lines and overexpressed in CD133 + CSCs compared to the corresponding CD133 -cells ( Supplementary Fig. 5E, F) . The knockdown of SMAD6 expression by siRNA could lead to a CD133 expression reduction ( Supplementary Fig. 5G, H) , which suggested that SMAD6 may contribute to the regulation of CD133 expression.
Transient Erk1/2 phosphorylation facilitates the BMP4-induced CD133 depression
Recent reports show that SMAD and MAPK pathways communicate through signaling crosstalk (25) . In this experiment, we found that BMP4 could induce Erk1/2 phosphorylation in a dose-dependent manner (Fig. 7A) . Furthermore, when we incubated cells with a particular concentration of BMP4 for different periods of time, Erk1/2 phosphorylation reached a peak at approximately 30 min, whereas at 5 min, Erk1/2 phosphorylation attained nearly a maximum concentration (Fig. 7B) .
To further ascertain the relationship between CD133 expression and Erk1/2 phosphorylation, HCC cells were incubated with the MEK inhibitors PD98059
and U0126. Treatment with either of the MEK inhibitors for 3 days induced the inhibition of Erk1/2 phosphorylation, which promoted CD133 protein expression (Fig. 7C ). Continuous treatment with either MEK inhibitor nearly abolished the BMP4-induced CD133 depression (Fig. 7D) . However, when the inhibitors were added 24 hrs after the BMP4 treatment, the CD133 expression was still reduced (Fig. 7D) , indicating that a short-term exposure to a high level of Erk1/2 phosphorylation plays a very important role in the BMP4-induced reduction of CD133 protein expression. However, After long-term (6 days) treatment of BMP4, Erk1/2 phosphorylation was inhibited in a dose-dependent manner in HCC cell lines, and the phosphorylation level of Erk1/2 was upregulated in CD133 + HCC cells ( Supplementary Fig. 6A, B) . Considering that cell growth was repressed after treatment with high-dose exogenous BMP4 or MEK inhibitors, we speculated that an adequate level of Erk1/2 phosphorylation may participate in the self-renewal of CSCs. 
Discussion
CSCs are thought to be responsible for the resistance of hepatic carcinoma to conventional therapies. Differentiation therapy could result in a loss of the CSC's self-renewal ability and the induction of terminal differentiation. The most successful application of differentiation therapy is the use of all-trans retinoic acid in acute premyelocytic leukemia, which is applied as a pro-differentiation inducer to enhance the chemotherapeutic effects (26) .
BMP4 plays an important role in the hepatogenesis, and BMP4 has been shown to induce rat hepatic progenitor cell differentiation (27) . Here, we The reported function of BMPs in cancers is inconsistent, and they are 
